1-3 of 3
Greg Pond, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Michael Savona, MD, Ramiro Garzon, MD, Peter de Nully Brown, MD, Karen Yee, MD, Jeffrey E. Lancet, MD, Martin Gutierrez, MD, Nashat Gabrail, MD, Morten Mau-Sorensen, MD, Rachid Baz, MD, John C. Byrd, MD, John Kuruvilla, MD, David S. Siegel, MD, PhD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, MSc, CCRP, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza, MD, Richard M. Stone, MD
Journal: Blood
Blood (2013) 122 (21): 1440.
https://doi.org/10.1182/blood.V122.21.1440.1440
Published: 2013
Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Christine I. Chen, MD, Martin Gutierrez, MD, Peter de Nully Brown, Nashat Gabrail, MD, Rachid Baz, MD, Donna E. Reece, MD, Michael Savona, MD, Suzanne Trudel, MD, MSC, FRCPC, David S. Siegel, MD, PhD, Morten Mau-Sorensen, MD, John Kuruvilla, MD, FRCPC, John C. Byrd, MD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, MSc, CCRP, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza, MD
Journal: Blood
Blood (2013) 122 (21): 1942.
https://doi.org/10.1182/blood.V122.21.1942.1942
Published: 2013
Journal Articles

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

John Kuruvilla, MD, Martin Gutierrez, MD, Bijal D. Shah, MD, Nashat Y. Gabrail, MD, Peter de Nully Brown, Richard M. Stone, MD, Ramiro Garzon, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Rachid Baz, MD, Morten Mau-Sorensen, MD, Matthew S. Davids, MD, John C. Byrd, MD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza
Journal: Blood
Blood (2013) 122 (21): 90.
https://doi.org/10.1182/blood.V122.21.90.90
Published: 2013